Local expression of indoleamine 2,3-dioxygenase suppresses T-cell-mediated rejection of an engineered bilayer skin substitute

Wound Repair and Regeneration

Volumn 18, Issue 6, 2010, Pages 614-623

  Forouzandeh, Farshad ^a   Jalili, Reza B ^a   Hartwell, Ryan V ^a   Allan, Sarah E ^b   Boyce, Steven ^c,d   Supp, Dorothy ^c,d   Ghahary, Aziz ^a  

^a Department of Surgery   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF CINCINNATI   (United States)

^d SHRINERS HOSPITALS FOR CHILDREN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD31 ANTIGEN; INDOLEAMINE 2,3 DIOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILAYER MEMBRANE; CELL CULTURE; CELL INFILTRATION; CONTROLLED STUDY; ENGRAFTMENT; FIBROBLAST; GRAFT REJECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; NEOVASCULARIZATION (PATHOLOGY); NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SKIN GRAFT; T LYMPHOCYTE; TISSUE ENGINEERING; VASCULARIZATION; WOUND HEALING; XENOGRAFT;

ADENOVIRIDAE; ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; FIBROBLASTS; GENETIC VECTORS; GRAFT REJECTION; IMMUNOSUPPRESSIVE AGENTS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; NEOVASCULARIZATION, PHYSIOLOGIC; RATS; RATS, SPRAGUE-DAWLEY; SKIN, ARTIFICIAL; T-LYMPHOCYTES; TISSUE ENGINEERING; TRANSFECTION; WOUND HEALING;

EID: 78349297207     PISSN: 10671927     EISSN: 1524475X     Source Type: Journal    
DOI: 10.1111/j.1524-475X.2010.00635.x     Document Type: Article

References (39)

1. Supp DM, Boyce ST., Engineered skin substitutes: practices and potentials. Clin Dermatol 2005; 23: 403-12.
2. Hemler ME., VLA proteins in the integrin family: structures, functions, and their role on leukocytes. Annu Rev Immunol 1990; 8: 365-400.
3. DeGraffenried LA, Isseroff RR., Wound dressings alter the colony-forming efficiency of keratinocytes in cultured sheet grafts. Cell Transplant 2001; 10: 749-54.
4. Greenhalgh DG., The role of growth factors in wound healing. J Trauma 1996; 41: 159-67.
5. Atiyeh BS, Costagliola M., Cultured epithelial autograft (CEA) in burn treatment: three decades later. Burns 2007; 33: 405-13.
6. Meuli M, Raghunath M., Burns (Part 2). Tops and flops using cultured epithelial autografts in children. Pediatr Surg Int 1997; 12: 471-7.
7. Medina A, Scott PG, Ghahary A, Tredget EE., Pathophysiology of chronic nonhealing wounds. J Burn Care Rehabil 2005; 26: 306-19.
8. Drukala J, Bandura L, Cieslik K, Korohoda W., Locomotion of human skin keratinocytes on polystyrene, fibrin, and collagen substrata and its modification by cell-to-cell contacts. Cell Transplant 2001; 10: 765-71.
9. Mitrani E, Nadel G, Hasson E, Harari E, Shimoni Y., Epithelial- mesenchymal interactions allow for epidermal cells to display an in vivo-like phenotype in vitro. Differentiation 2005; 73: 79-87.
10. Sawicki G, Marcoux Y, Sarkhosh K, Tredget EE, Ghahary A., Interaction of keratinocytes and fibroblasts modulates the expression of matrix metalloproteinases-2 and -9 and their inhibitors. Mol Cell Biochem 2005; 269: 209-16.
11. Coulomb B, Friteau L, Baruch J, Guilbaud J, Chretien-Marquet B, Glicenstein J, Lebreton-Decoster C, Bell E, Dubertret L., Advantage of the presence of living dermal fibroblasts within in vitro reconstructed skin for grafting in humans. Plast Reconstr Surg 1998; 101: 1891-903.
12. Funeshima-Fuji N, Fujino M, Kimura H, Takahara S, Nakayama T, Ezaki T, Li XK., Survival of skin allografts is prolonged in mice with a dominant-negative H-Ras. Transpl Immunol 2008; 18: 302-6.
13. He C, Heeger PS., CD8 T cells can reject major histocompatibility complex class I-deficient skin allografts. Am J Transplant 2004; 4: 698-704.
14. Eichwald EJ, Barstad R, Graves G., Cell-mediated hyperacute rejection. III. Genetic determinants. Immunogenetics 1981; 14: 351-5.
15. Tredget EE, Shankowsky HA, Pannu R, Nedelec B, Iwashina T, Ghahary A, Taerum TV, Scott PG., Transforming growth factor-beta in thermally injured patients with hypertrophic scars: effects of interferon alpha-2b. Plast Reconstr Surg 1998; 102: 1317-28.
16. Mellor AL, Munn DH., IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004; 4: 762-74.
17. Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, Brown C, Mellor AL., Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998; 281: 1191-3.
18. Alexander AM, Crawford M, Bertera S, Rudert WA, Takikawa O, Robbins PD, Trucco M., Indoleamine 2,3-dioxygenase expression in transplanted NOD Islets prolongs graft survival after adoptive transfer of diabetogenic splenocytes. Diabetes 2002; 51: 356-65.
19. Forouzandeh F, Jalili RB, Germain M, Duronio V, Ghahary A., Differential immunosuppressive effect of indoleamine 2,3-dioxygenase (IDO) on primary human CD4(+) and CD8 (+) T cells. Mol Cell Biochem 2008; 309: 1-7.
20. Ghahary A, Li Y, Tredget EE, Kilani RT, Iwashina T, Karami A, Lin X., Expression of indoleamine 2,3-dioxygenase in dermal fibroblasts functions as a local immunosuppressive factor. J Invest Dermatol 2004; 122: 953-64.
21. Jalili RB, Forouzandeh F, Bahar MA, Ghahary A., The immunoregulatory function of indoleamine 2, 3 dioxygenase and its application in allotransplantation. Iran J Allergy Asthma Immunol 2007; 6: 167-79.
22. Jalili RB, Rayat GR, Rajotte RV, Ghahary A., Suppression of islet allogeneic immune response by indoleamine 2,3 dioxygenase-expressing fibroblasts. J Cell Physiol 2007; 213: 137-43.
23. Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, Boon T, Van den Eynde BJ., Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003; 9: 1269-74.
24. Yoshida R, Imanishi J, Oku T, Kishida T, Hayaishi O., Induction of pulmonary indoleamine 2,3-dioxygenase by interferon. Proc Natl Acad Sci USA 1981; 78: 129-32.
25. Hayashi T, Beck L, Rossetto C, Gong X, Takikawa O, Takabayashi K, Broide DH, Carson DA, Raz E., Inhibition of experimental asthma by indoleamine 2,3-dioxygenase. J Clin Invest 2004; 114: 270-9.
26. Grohmann U, Fallarino F, Bianchi R, Vacca C, Orabona C, Belladonna ML, Fioretti MC, Puccetti P., Tryptophan catabolism in nonobese diabetic mice. Adv Exp Med Biol 2003; 527: 47-54.
27. Li Y, Tredget EE, Ghaffari A, Lin X, Kilani RT, Ghahary A., Local expression of indoleamine 2,3-dioxygenase protects engraftment of xenogeneic skin substitute. J Invest Dermatol 2006; 126: 128-36.
28. Li Y, Tredget EE, Ghahary A., Cell surface expression of MHC class I antigen is suppressed in indoleamine 2,3-dioxygenase genetically modified keratinocytes: implications in allogeneic skin substitute engraftment. Hum Immunol 2004; 65: 114-23.
29. Forouzandeh F, Jalili RB, Germain M, Duronio V, Ghahary A., Skin cells, but not T cells, are resistant to indoleamine 2, 3-dioxygenase (IDO) expressed by allogeneic fibroblasts. Wound Repair Regen 2008; 16: 379-87.
30. Sarkhosh K, Tredget EE, Li Y, Kilani RT, Uludag H, Ghahary A., Proliferation of peripheral blood mononuclear cells is suppressed by the indoleamine 2,3-dioxygenase expression of interferon-gamma-treated skin cells in a co-culture system. Wound Repair Regen 2003; 11: 337-45.
31. Boyce ST, Christianson DJ, Hansbrough JF., Structure of a collagen-GAG dermal skin substitute optimized for cultured human epidermal keratinocytes. J Biomed Mater Res 1988; 22: 939-57.
32. Boyce ST, Foreman TJ, English KB, Stayner N, Cooper ML, Sakabu S, Hansbrough JF., Skin wound closure in athymic mice with cultured human cells, biopolymers, and growth factors. Surgery 1991; 110: 866-76.
33. Ghahary A, Tredget EE, Shen Q, Kilani RT, Scott PG, Houle Y., Mannose-6-phosphate/IGF-II receptors mediate the effects of IGF-1-induced latent transforming growth factor beta 1 on expression of type I collagen and collagenase in dermal fibroblasts. Growth Factors 2000; 17: 167-76.
34. Boyce ST, Supp AP, Harriger MD, Greenhalgh DG, Warden GD., Topical nutrients promote engraftment and inhibit wound contraction of cultured skin substitutes in athymic mice. J Invest Dermatol 1995; 104: 345-9.
35. Erdag G, Morgan JR., Allogeneic versus xenogeneic immune reaction to bioengineered skin grafts. Cell Transplant 2004; 13: 701-12.
36. Llames SG, Del RM, Larcher F, Garcia E, Garcia M, Escamez MJ, Jorcano JL, Holguin P, Meana A., Human plasma as a dermal scaffold for the generation of a completely autologous bioengineered skin. Transplantation 2004; 77: 350-5.
37. Liu H, Liu L, Fletcher BS, Visner GA., Novel action of indoleamine 2,3-dioxygenase attenuating acute lung allograft injury. Am J Respir Crit Care Med 2006; 173: 566-72.
38. Beutelspacher SC, Pillai R, Watson MP, Tan PH, Tsang J, McClure MO, George AJ, Larkin DF., Function of indoleamine 2,3-dioxygenase in corneal allograft rejection and prolongation of allograft survival by over-expression. Eur J Immunol 2006; 36: 690-700.
39. Liu L, Marti GP, Wei X, Zhang X, Zhang H, Liu YV, Nastai M, Semenza GL, Harmon JW., Age-dependent impairment of HIF-1alpha expression in diabetic mice: correction with electroporation-facilitated gene therapy increases wound healing, angiogenesis, and circulating angiogenic cells. J Cell Physiol 2008; 217: 319-27.